Without a defined standard of care for tapering GLP-1 medications, physicians must navigate patient management amid insurer restrictions and high discontinuation rates
Rituximab-treated patients with rheumatic disease had diminished antibody levels and impaired CD8+ T-cell responses after SARS-CoV-2 infection and vaccination, though CD4+ responses remained intact.
Following court injunctions, some states and cities regained funding, while others experienced continued cancellations that affected immunization clinics, workforce capacity, and infectious-disease surveillance.
Emails and interviews show CDC scientists were sidelined during the West Texas surge, leaving local officials without guidance as cases spread across the US and into Mexico.